| Cost-effectiveness analysis of five systemic treatments for unresectable hepatocellular carcinoma in China: an economic evaluation based on network meta-analysis M Zhao, X Pan, Y Yin, H Hu, J Wei, Z Bai, W Tang Frontiers in Public Health 10, 869960, 2022 | 26 | 2022 |
| Serplulimab plus chemotherapy vs chemotherapy for treatment of US and Chinese patients with extensive-stage small-cell lung cancer: a cost-effectiveness analysis to inform drug … T Shao, M Zhao, L Liang, W Tang BioDrugs 37 (3), 421-432, 2023 | 15 | 2023 |
| Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma T Shao, M Zhao, W Tang Frontiers in Oncology 12, 953671, 2022 | 11 | 2022 |
| Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China T Shao, Y Ren, M Zhao, W Tang Frontiers in Public Health 10, 912921, 2022 | 10 | 2022 |
| Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non … M Zhao, T Shao, Z Chi, W Tang Frontiers in Public Health 11, 1051484, 2023 | 7 | 2023 |
| A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer T Shao, M Zhao, L Liang, W Tang Frontiers in Immunology 13, 948597, 2022 | 7 | 2022 |
| Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network … M Zhao, T Shao, Y Ren, C Zhou, W Tang Frontiers in Pharmacology 13, 910656, 2022 | 7 | 2022 |
| Cost-effectiveness analysis of colonoscopy and fecal immunochemical testing for colorectal cancer screening in China Y Ren, M Zhao, D Zhou, Q Xing, F Gong, W Tang Frontiers in Public Health 10, 952378, 2022 | 7 | 2022 |
| Economic evaluation of nemonoxacin, moxifloxacin and levofloxacin in the treatment of early community-acquired pneumonia with possible pulmonary tuberculosis M Zhao, Z Chi, X Pan, Y Yin, W Tang International Journal of Environmental Research and Public Health 19 (8), 4816, 2022 | 5 | 2022 |
| Impacts of systemic treatments on health-related quality of life for patients with metastatic colorectal cancer: a systematic review and network meta-analysis Y Jiang, M Zhao, W Tang, X Zheng BMC cancer 24 (1), 188, 2024 | 3 | 2024 |
| Traffic Flow Prediction and Analysis in Smart Cities Based on the WND‐LSTM Model SY Ma, MY Zhao Computational intelligence and neuroscience 2022 (1), 7079045, 2022 | 2 | 2022 |
| QALY-type preference and willingness-to-pay among end-of-life patients with cancer treatments: a pilot study using discrete choice experiment Y Yin, Q Peng, L Ma, Y Dong, Y Sun, S Xu, N Ding, X Liu, M Zhao, Y Tang, ... Quality of Life Research 33 (3), 753-765, 2024 | 1 | 2024 |
| Cost-effectiveness analysis of atezolizumab in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen: a United Kingdom health … Y Jiang, M Zhao, J Xi, J Li, W Tang, X Zheng Frontiers in Public Health 11, 1282374, 2023 | 1 | 2023 |
| Impact of extrapolation model choices on the structural uncertainty in economic evaluations for cancer immunotherapy: a case study of checkmate 067 T Shao, M Zhao, L Liang, L Shi, W Tang PharmacoEconomics-Open 7 (3), 383-392, 2023 | 1 | 2023 |
| Effectiveness and cost-effectiveness of non-pharmacological interventions among chinese adults with prediabetes: a protocol for network meta-analysis and CHIME-modeled cost … Y Yin, Y Tu, M Zhao, W Tang International Journal of Environmental Research and Public Health 19 (3), 1622, 2022 | 1 | 2022 |
| Identifying optimal ALK inhibitors in first-and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta … M Zhao, T Shao, H Shao, C Zhou, W Tang BMC cancer 24 (1), 186, 2024 | | 2024 |
| A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced … H Shao, M Zhao, AJ Guan, T Shao, D Zhou, G Yu, W Tang BMC medicine 22 (1), 13, 2024 | | 2024 |
| Sotorasib versus Docetaxel for treatment of US and Chinese patients with advanced non-small-cell lung cancer with KRAS p. G12C-mutated: A cost-effectiveness analysis to inform … Y Jiang, M Zhao, R Liu, X Zheng Medicine 102 (50), e36387, 2023 | | 2023 |
| Estimating the cost-effectiveness threshold of advanced non-small cell lung cancer in China using mean opportunity cost and contingent valuation method Q Peng, Y Yin, M Liang, M Zhao, T Shao, Y Tang, Z Mei, H Li, W Tang Cost Effectiveness and Resource Allocation 21 (1), 80, 2023 | | 2023 |
| Cost-effectiveness and potential budget impact of non-pharmacological interventions for early management in prehypertensive people: an economic evaluation for China L Liang, T Shao, H Li, M Zhao, W Tang BMC Public Health 23 (1), 1531, 2023 | | 2023 |
